Saloni Dattani and Jacob Trefethen discuss siRNA medicines that suppress production of harmful proteins without changing DNA. They examine the long path from discovery to treatment, why existing drugs concentrate on liver diseases, programmable and long-lasting effects, and prospects and limitations for treating infection, cardiovascular disease, rare disorders and cancer.
In Biotechnology and Genetics